NCT00486278 - Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Congenital Bleeding DisorderHaemophilia AHaemophilia B

Interventions

DRUG

eptacog alfa (activated)

90 mcg/kg, injected i.v.

DRUG

vatreptacog alfa (activated)

5 mcg/kg, injected i.v.

DRUG

vatreptacog alfa (activated)

10 mcg/kg, injected i.v.

DRUG

vatreptacog alfa (activated)

20 mcg/kg, injected i.v.

DRUG

vatreptacog alfa (activated)

40 mcg/kg, injected i.v.

DRUG

vatreptacog alfa (activated)

80 mcg/kg, injected i.v.

Trial Locations (45)

100

Novo Nordisk Investigational Site, Taipei

500

Novo Nordisk Investigational Site, Changhua

2193

Novo Nordisk Investigational Site, Parktown Johannesburg

4012

Novo Nordisk Investigational Site, Debrecen

4013

Novo Nordisk Investigational Site, Durban

7925

Novo Nordisk Investigational Site, Cape Town

10029

Novo Nordisk Investigational Site, New York

10400

Novo Nordisk Investigational Site, Bangkok

20124

Novo Nordisk Investigational Site, Milan

28046

Novo Nordisk Investigational Site, Madrid

30912

Novo Nordisk Investigational Site, Augusta

31033

Novo Nordisk Investigational Site, Castelfranco Veneto

35100

Novo Nordisk Investigational Site, Bornova-IZMIR

45229

Novo Nordisk Investigational Site, Cincinnati

46260

Novo Nordisk Investigational Site, Indianapolis

50134

Novo Nordisk Investigational Site, Florence

50400

Novo Nordisk Investigational Site, Kuala Lumpur

52242

Novo Nordisk Investigational Site, Iowa City

52621

Novo Nordisk Investigational Site, Tel Litwinsky

55455

Novo Nordisk Investigational Site, Minneapolis

69003

Novo Nordisk Investigational Site, Lyon

90027

Novo Nordisk Investigational Site, Los Angeles

13081970

Novo Nordisk Investigational Site, Campinas

60612-3833

Novo Nordisk Investigational Site, Chicago

02115

Novo Nordisk Investigational Site, Boston

48109-5235

Novo Nordisk Investigational Site, Ann Arbor

27599-7035

Novo Nordisk Investigational Site, Chapel Hill

97239-3011

Novo Nordisk Investigational Site, Portland

C1425ASU

Novo Nordisk Investigational Site, Ciudad Autónoma de Bs. As.

20211-030

Novo Nordisk Investigational Site, Rio de Janeiro

04024-002

Novo Nordisk Investigational Site, São Paulo

T6G 2B7

Novo Nordisk Investigational Site, Edmonton

10 000

Novo Nordisk Investigational Site, Zagreb

H-1134

Novo Nordisk Investigational Site, Budapest

734 8551

Novo Nordisk Investigational Site, Hiroshima-shi, Hiroshima

173 8606

Novo Nordisk Investigational Site, Itabashi-ku, Tokyo

634 8522

Novo Nordisk Investigational Site, Kashihara-shi, Nara

466 8560

Novo Nordisk Investigational Site, Nagoya-shi, Aichi

663 8051

Novo Nordisk Investigational Site, Nishinomiya-shi

02-776

Novo Nordisk Investigational Site, Warsaw

01130

Novo Nordisk Investigational Site, Adana

06100

Novo Nordisk Investigational Site, Ankara

01010

Novo Nordisk Investigational Site, Antalya

SE1 7EH

Novo Nordisk Investigational Site, London

M13 9WL

Novo Nordisk Investigational Site, Manchester